Skip to main content

Table 3 ALN metastasis burden between the FNA and SLNB groups stratified by tumor stage

From: Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era

 

T1

T2

FNA

(N = 61)

SLNB

(N = 77)

P value

FNA

(N = 141)

SLNB

(N = 109)

P value

No. of ALN removed [mean (95% CI)]

19.38 (18.07–20.69)

18.30 (17.21–19.39)

0.205

20.21 (19.28–21.13)

19.54 (18.52–20.57)

0.344

No. of positive ALN [mean (95% CI)]

4.26 (3.31–5.21)

1.51 (1.27–1.74)

< 0.001

5.57 (4.60–6.55)

1.96 (1.53–2.39)

< 0.001

No. of positive ALN

  

< 0.001

  

< 0.001

 1+

13 (21.31)

52 (67.53)

 

20 (14.18)

67 (61.47)

 

 2+

16 (26.23)

20 (25.97)

 

35 (24.82)

25 (22.94)

 

 ≥ 3+

32 (52.46)

5 (6.49)

 

86 (60.99)

17 (15.60)

 
  1. ALN axillary lymph node, FNA fine-needle aspiration, SLNB sentinel lymph node biopsy